Hikal Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/64kpq7pe5d6gxe6z2ttt9ttx.pdf

Key Takeaways


Margin Walk: The Input Cost Shock & Recovery Path

Manoj Mehrotra: "It's a little uncertain at this stage. We'll definitely see improvement in Q3 and Q4 because the raw material prices have softened. And if the same trend continues, I'll say, if I take a guess three quarters, it will be back to where we were."

Segment Performance

SegmentRevenue (Q2 FY23)YoY GrowthEBIT MarginCommentary
Crop Protection₹269 crores▲ 42%13.1%Strong demand for own products domestically and higher forecast from global innovators; plants at full capacity with ~10% spare capacity and debottlenecking underway.
Pharma₹290 crores▲ 4%3.0%Subdued growth from temporary demand softening for key products; API volumes healthy but CDMO volumes hit by customer inventory correction, expected to normalize from Q1 2023.

The CDMO Pivot & Pharma Pipeline

Sameer Hiremath: "Next year itself will be large part of our business will shift on the pharma side towards the CDMO."

Capex Cycle: New Assets, Delayed Revenue

Sameer Hiremath: "With an EBITDA margin that in excess of what we have historically pre September '21 numbers, well over 20% EBITDA margins."

NGT Liability: A Contained Risk

Sameer Hiremath: "Even if we have to, the chances of us to ask to pay the entire amount is extremely low. There are several recourses and things we see of NGT recommendation made in the past for all chemical incidences in the past have resulted in stay by the Supreme Court. And even any amounts have to be paid, there's a very nominal amount."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenueConfident of beating overall FY22 revenuesFY23
Quarterly revenue run rateMaintain ~₹550 crores and do slightly better quarter-on-quarterQ3 and Q4 FY23
Margin recoveryReturn to September/December 2021 margin levelsQ1 to Q2 FY24
Pharma EBIT marginRevert to mid-teen margins, provided raw material softening continuesQ1/Q2 FY24
Fungicide plant commissioningPlant commissioned, revenue accrual begins subsequentlyQ4 FY23
Animal Health facilityMultipurpose manufacturing facility on streamQ1 FY24
Animal Health commercializationCommercial supply starts after DMF filings, validation, and approvalsFY25 onwards
CDMO product launchesAt least 2 to 3 products planned, dependent on customer launch strategyFY24
New capex asset turnsPeak asset turnover of 1.4 to 1.5x reached24 to 30 months from commissioning

Key Metrics

MetricQ2 FY23
Revenue₹559 cr, +19% YoY from ₹469 cr in Q2 FY22
H1 FY23 revenue₹938 cr, flat YoY
EBITDA₹70 cr, vs ₹91 cr in Q2 FY22
H1 FY23 EBITDA₹92 cr
PAT₹25 cr, vs ₹44 cr in Q2 FY22 and loss of ₹9 cr in Q1 FY23
Crop Protection revenue₹269 cr, +42% YoY from ₹190 cr in Q2 FY22
Crop Protection EBIT margin13.1%, EBIT of ₹35.3 cr
Pharma revenue₹290 cr, +4% YoY from ₹280 cr in Q2 FY22
Pharma EBIT margin3%, EBIT of ₹10.6 cr
Volume growth12% YoY; H1 volume growth slightly negative
Crop capacity utilization~90%, with ~10% spare capacity available
Net debt₹742 cr, up marginally from ₹690 cr in Q1 FY23
CWIP₹309 cr, largely for crop plant commissioning in Q4 FY23
Credit ratingA+ by ICRA, long-term